Fig. 7: Complement inhibitory treatment protects against migrasome mediated BBB injury.

Healthy C57/BL6 WT mice (age = 8-10w) were treated with 4 serial doses of Raw264.7 cell derived migrasomes (10 mg/kg, i.v. injected at day 1, 2, 3, 5) in addition with PMX-53 treatment (0.25 mg per mouse, o.p.). Six days after the first migrasome injection (day 7), recipients were injected with 10 mg/kg 3kDa-Dextran at 90 min before sacrifice. Mice were perfused with PBS then 4% paraformaldehyde after peripheral blood collection. N = 6 in each group. a Coronal brain sections of the recipients were collected and subjected to immunostaining of CD31 (green) and ZO-1 (red) to evaluate the tight junction integrity. b Leakage of 3kDa-Dextran in the brain parenchyma was assessed with fluorescent microscopy. c Plasma NeFL concentration of the recipients. N = 6 mice in each group. Data are presented as mean values ± SEM with the indicated significance (compared with PBS-M transferred group by one-way ANOVA followed by Tukey’s post-test). d Fluorescent intensity of 3kDa-Dextran in the plasma and eye balls of the recipients. N = 6 mice in each group. Data are presented as mean values ± SEM with the indicated significance (compared with PBS-M transferred group by one-way ANOVA followed by Tukey’s post-test). e White matter integrity of recipients was assessed with MBP immunostaining. MBP MFI in striatum (STR) and cortex (CTX) was calculated. N = 6 mice in each group. Statistics outcomes were presented in Fig. S16d. Source data are provided as a Source Data file.